NL301050I2 - Relebactam of het monohydraat ervan - Google Patents

Relebactam of het monohydraat ervan Download PDF

Info

Publication number: NL301050I2
Authority: NL; Netherlands
Prior art keywords: relebactam; monohydrate
Prior art date: 2008-01-18

Application number

NL301050C

Other languages

English (en)

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-18

Filing date

2020-06-25

Publication date

2020-09-03

2020-06-25 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2020-09-03 Publication of NL301050I2 publication Critical patent/NL301050I2/nl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyrrole Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

NL301050C 2008-01-18 2020-06-25 Relebactam of het monohydraat ervan NL301050I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1153308P	2008-01-18	2008-01-18
PCT/US2009/031047 WO2009091856A2 (en)	2008-01-18	2009-01-15	Beta-lactamase inhibitors

Publications (1)

Publication Number	Publication Date
NL301050I2 true NL301050I2 (nl)	2020-09-03

Family

ID=40642204

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NL301050C NL301050I2 (nl)	2008-01-18	2020-06-25	Relebactam of het monohydraat ervan
NL301051C NL301051I2 (nl)	2008-01-18	2020-06-25	Relebactam, desgewenst in de vorm van het monohydraat, en imipenem

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NL301051C NL301051I2 (nl)	2008-01-18	2020-06-25	Relebactam, desgewenst in de vorm van het monohydraat, en imipenem

Country Status (38)

Country	Link
US (2)	US8487093B2 (nl)
EP (2)	EP2231667B1 (nl)
JP (3)	JP5038509B2 (nl)
KR (2)	KR101648728B1 (nl)
CN (2)	CN102827067B (nl)
AU (1)	AU2009206119C1 (nl)
BR (1)	BRPI0906871B1 (nl)
CA (1)	CA2712783C (nl)
CO (1)	CO6331438A2 (nl)
CR (1)	CR11626A (nl)
CY (5)	CY1114900T1 (nl)
DK (2)	DK2666774T3 (nl)
DO (1)	DOP2010000218A (nl)
EC (2)	ECSP10010345A (nl)
ES (2)	ES2433744T3 (nl)
FR (3)	FR20C1031I2 (nl)
HN (1)	HN2010001395A (nl)
HR (2)	HRP20131123T1 (nl)
HU (2)	HUS2000023I1 (nl)
IL (1)	IL206395A (nl)
LT (3)	LTPA2020517I1 (nl)
LU (1)	LUC00165I2 (nl)
MA (1)	MA32025B1 (nl)
ME (1)	ME02089B (nl)
MX (1)	MX2010007823A (nl)
MY (1)	MY162532A (nl)
NI (1)	NI201000115A (nl)
NL (2)	NL301050I2 (nl)
NO (3)	NO2020024I1 (nl)
NZ (1)	NZ586861A (nl)
PL (2)	PL2666774T3 (nl)
PT (2)	PT2231667E (nl)
RS (2)	RS53052B (nl)
RU (1)	RU2445314C9 (nl)
SI (2)	SI2666774T1 (nl)
UA (1)	UA101966C2 (nl)
WO (1)	WO2009091856A2 (nl)
ZA (1)	ZA201005333B (nl)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009091856A2 (en) *	2008-01-18	2009-07-23	Merck & Co., Inc.	Beta-lactamase inhibitors
KR102205755B1 (ko)	2010-08-10	2021-01-22	렘펙스 파머수티클스 인코퍼레이티드	고리형 보론산 에스터 유도체의 결정 형태
US8772490B2 (en)	2010-12-22	2014-07-08	Meiji Seika Pharma Co., Ltd.	Optically active diazabicyclooctane derivatives and process for preparing the same
HUE032491T2 (en)	2010-12-22	2017-09-28	Meiji Seika Pharma Co Ltd	An optically active diaza-bicyclooctane derivative and a process for its preparation
WO2012172368A1 (en) *	2011-06-17	2012-12-20	Astrazeneca Ab	Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
US8822450B2 (en) *	2011-08-27	2014-09-02	Wockhardt Ltd.	1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
KR101618424B1 (ko) *	2011-08-30	2016-05-04	욱크하르트 리미티드	1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
US9012491B2 (en)	2011-08-31	2015-04-21	Rempex Pharmaceuticals, Inc.	Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8796257B2 (en)	2011-12-02	2014-08-05	Naeja Pharmaceutical Inc.	Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en)	2011-12-02	2016-11-29	Fedora Pharmaceuticals Inc.	Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
AU2013207510A1 (en)	2012-01-06	2014-07-31	The Regents Of The University Of California	Compositions, methods of use, and methods of treatment
EP2831075B1 (en) *	2012-03-30	2017-11-08	Merck Sharp & Dohme Corp.	1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8969570B2 (en)	2012-03-30	2015-03-03	Cubist Pharmaceuticals, Inc.	Beta-lactamase inhibitors
CA2869051A1 (en) *	2012-03-30	2013-10-03	Cubist Pharmaceuticals, Inc.	Isoxazole .beta.-lactamase inhibitors
US8916709B2 (en)	2012-03-30	2014-12-23	Cubist Pharmaceuticals, Inc.	1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es)	2012-04-02	2014-11-19	Astrazeneca Ab	COMPUESTOS INHIBIDORES DE b LACTAMASA
SG11201407295YA (en)	2012-05-08	2014-12-30	Codexis Inc	Biocatalysts and methods for hydroxylation of chemical compounds
US9156858B2 (en)	2012-05-23	2015-10-13	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
NZ701959A (en) *	2012-05-30	2016-07-29	Meiji Seika Pharma Co Ltd	Novel β-lactamase inhibitor and method for producing same
US10561675B2 (en)	2012-06-06	2020-02-18	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX368346B (es)	2012-08-25	2019-09-27	Wockhardt Ltd	Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas.
WO2014069351A1 (ja)	2012-11-01	2014-05-08	株式会社カネカ	光学活性二環式ウレア化合物の製造方法
PT2928898T (pt)	2012-12-07	2021-07-05	Venatorx Pharmaceuticals Inc	Inibidores de beta-lactamase
UA111925C2 (uk) *	2012-12-11	2016-06-24	Федора Фармасьютікалз Інк.	БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9642869B2 (en)	2013-01-04	2017-05-09	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
CN104981239B (zh)	2013-01-04	2019-01-04	莱姆派克斯制药公司	硼酸衍生物及其治疗用途
US9101638B2 (en)	2013-01-04	2015-08-11	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en)	2013-01-04	2016-01-26	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
JP6346904B2 (ja)	2013-01-10	2018-06-20	ベナトルクスファーマシューティカルズ，インク．	ベータ−ラクタマーゼ阻害剤
US9556174B2 (en)	2013-03-08	2017-01-31	Wockhardt Limited	(2S, 5R)-sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
KR101774132B1 (ko)	2013-03-08	2017-09-01	욱크하르트 리미티드	(2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
JP6285970B2 (ja) *	2013-03-08	2018-02-28	ウォックハートリミテッド	（２ｓ，５ｒ）−７−オキソ−６−スルホオキシ−２−［（（３ｒ）−ピロリジン−３−カルボニル）−ヒドラジノカルボニル］−１，６−ジアザ−ビシクロ［３．２．１］オクタンの調製のためのプロセス
CA2904089C (en) *	2013-03-08	2017-05-02	Wockhardt Limited	A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
WO2014135931A1 (en) *	2013-03-08	2014-09-12	Wockhardt Limited	A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
RU2627700C2 (ru)	2013-03-08	2017-08-10	Вокхардт Лимитед	Способ получения (2s,5r)-7-оксо-6-сульфоокси-2-[((3r)-пиперидин-3-карбонил)-гидразинокарбонил]-1,6-диазабицикло[3.2.1]октана
EP2970338A1 (en)	2013-03-14	2016-01-20	Merck Sharp & Dohme Corp.	Crystalline form of a beta-lactamase inhibitor
EP2970340B1 (en)	2013-03-14	2020-02-12	Venatorx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
CA2911544A1 (en) *	2013-06-10	2014-12-18	Merck Sharp & Dohme Corp.	Preparation of tert-butyl 4-((1r,2s,5r)-6-(benzyloxy)-7-0x0-1,6-diazabicycl0[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate
NZ718009A (en)	2013-09-24	2018-03-23	Meiji Seika Pharma Co Ltd	Process for producing diazabicyclooctane derivative and intermediate thereof
WO2015051101A1 (en) *	2013-10-02	2015-04-09	Cubist Pharmaceuticals, Inc.	B-lactamase inhibitor picoline salt
EP3067355B1 (en)	2013-10-08	2020-12-16	Meiji Seika Pharma Co., Ltd.	Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
US9604986B2 (en)	2013-11-26	2017-03-28	Wockhardt Limited	Polymorphs and process for preparation of (2S, 5R)-7-oxo-N-[(2S)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
KR101733441B1 (ko)	2014-03-24	2017-05-10	노파르티스 아게	박테리아 감염의 치료를 위한 모노박탐 유기 화합물
IN2014MU01195A (nl) *	2014-03-29	2015-10-02	Wockhardt Ltd
WO2015150890A1 (en) *	2014-03-29	2015-10-08	Wockhardt Limited	A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester
ES2985626T3 (es)	2014-05-05	2024-11-06	Melinta Therapeutics Inc	Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
RS59488B1 (sr)	2014-05-05	2019-12-31	Rempex Pharmaceuticals Inc	Sinteza boronatnih soli i njihove upotrebe
KR20170007448A (ko)	2014-05-19	2017-01-18	렘펙스 파머수티클스 인코퍼레이티드	보론산 유도체 및 그의 치료적 용도
EP3882252B1 (en)	2014-06-11	2025-11-19	Venatorx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
US9511142B2 (en)	2014-06-11	2016-12-06	VenatoRx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
MX2016016666A (es)	2014-07-01	2017-08-08	Rempex Pharmaceuticals Inc	Derivados de acido boronico y usos terapeuticos de los mismos.
HUE044061T2 (hu)	2014-11-17	2019-09-30	Entasis Therapeutics Ltd	Kombinációs terápia rezisztens bakteriális fertõzések kezelésére
WO2016081297A1 (en)	2014-11-18	2016-05-26	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2812848T3 (es)	2014-12-02	2021-03-18	Merck Sharp & Dohme	Proceso para la preparación de 4-((2S,5R)-6-(benciloxi)-7-oxo-1,6-diazabiciclo[3.2.1]octano-2-carboxamido)piperidin-1-carboxilato de terc-butilo y análogos del mismo
SG11201704576SA (en)	2014-12-05	2017-07-28	Meiji Seika Pharma Co Ltd	Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US20180051041A1 (en)	2015-03-17	2018-02-22	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
AU2016239207A1 (en)	2015-03-31	2017-10-12	Mutabilis	Heterocyclic compounds and their use in preventing or treating bacterial infections
TWI754613B (zh) *	2015-05-07	2022-02-11	法商木塔比利斯公司	雜環化合物及其用於預防或治療細菌感染之用途
EP3347008B1 (en)	2015-09-11	2022-03-09	Venatorx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
JP2018515481A (ja) *	2015-09-16	2018-06-14	シュアンチューファーマカンパニー，リミティド	β−ラクタマーゼ阻害剤とその利用
WO2017055922A1 (en)	2015-10-02	2017-04-06	Legochem Biosciences, Inc.	Compositions and methods for inhibiting beta-lactamase
WO2017100537A1 (en)	2015-12-10	2017-06-15	VenatoRx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
KR20180094042A (ko) *	2015-12-11	2018-08-22	욱크하르트 리미티드	7-옥소-6-(설포옥시)-1,6-디아자바이사이클로[3.2.1]옥탄-2-카르복사미드 함유 화합물 및 이의 세균 감염의 치료 용도
WO2017136254A1 (en)	2016-02-04	2017-08-10	Merck Sharp & Dohme Corp.	Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
CN108778270B (zh) *	2016-03-31	2021-07-30	吉林四环制药有限公司	一种抗菌组合物及其用途
IL263448B2 (en)	2016-06-09	2023-10-01	Codexis Inc	Biological catalysts and methods for hydroxylation of chemical compounds
CN109415386B (zh)	2016-06-30	2022-04-19	Qpex生物制药有限公司	硼酸衍生物及其治疗用途
EP3494121B1 (en)	2016-08-04	2021-10-06	Venatorx Pharmaceuticals, Inc.	Boron-containing compounds
AU2017325863B2 (en) *	2016-09-16	2021-08-19	Entasis Therapeutics Limited	Beta-lactamase inhibitor compounds
US10464937B2 (en) *	2016-09-19	2019-11-05	Merck Sharp & Dohme Corp.	Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
JOP20190061A1 (ar)	2016-09-28	2019-03-26	Novartis Ag	مثبطات بيتا-لاكتاماز
CN108078982B (zh) *	2016-11-21	2020-02-07	天津大学	脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
PL3592362T3 (pl)	2017-03-06	2025-06-23	VenatoRx Pharmaceuticals, Inc.	Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania
CN108619141B (zh) *	2017-03-16	2021-09-10	山东轩竹医药科技有限公司	一种抗菌组合物及其用途
DK3630111T3 (en)	2017-05-08	2022-03-14	Entasis Therapeutics Inc	Compounds and methods for treating bacterial infections
US10085999B1 (en)	2017-05-10	2018-10-02	Arixa Pharmaceuticals, Inc.	Beta-lactamase inhibitors and uses thereof
US11332485B2 (en)	2017-05-26	2022-05-17	VenatoRx Pharmaceuticals, Inc.	Penicillin-binding protein inhibitors
US11267826B2 (en)	2017-05-26	2022-03-08	VenatoRx Pharmaceuticals, Inc.	Penicillin-binding protein inhibitors
WO2019016393A1 (en)	2017-07-21	2019-01-24	Antabio Sas	CHEMICAL COMPOUNDS
CN109568323B (zh) *	2017-09-29	2022-09-30	吉林四环制药有限公司	抗菌组合物及其用途
EP3694864B1 (en)	2017-10-11	2025-03-05	Qpex Biopharma, Inc.	Boronic acid derivatives and synthesis thereof
WO2019105479A1 (zh)	2017-12-01	2019-06-06	南京明德新药研发股份有限公司	一种β-内酰胺酶抑制剂的晶型及其制备方法
CN109956941B (zh) *	2017-12-25	2020-08-04	新发药业有限公司	一种阿维巴坦的简便制备方法
KR102769880B1 (ko)	2018-01-25	2025-02-20	쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디.	β-락타마제 억제제 및 그 용도
WO2019204419A1 (en)	2018-04-20	2019-10-24	The Medicines Company (San Diego), Llc	Boronic acid derivatives and therapeutic uses thereof
EP3572411A1 (en)	2018-05-21	2019-11-27	Antabio SAS	Thiazole derivatives as metallo-beta-lactamase inhibitors
WO2019226931A1 (en)	2018-05-25	2019-11-28	VenatoRx Pharmaceuticals, Inc.	Penicillin-binding protein inhibitors
CA3110111A1 (en) *	2018-08-09	2020-02-13	Antabio Sas	Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en)	2018-08-09	2024-02-20	Antabio Sas	Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3670512A1 (en) *	2018-12-18	2020-06-24	Antabio SAS	Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3854786A4 (en) *	2018-09-21	2022-09-14	API Corporation	PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES
US11180500B2 (en)	2018-10-01	2021-11-23	Arixa Pharmaceuticals, Inc.	Derivatives of relebactam and uses thereof
CN111072660B (zh) *	2018-10-22	2021-05-18	新发药业有限公司	一种瑞来巴坦的简便制备方法
EP3938366A1 (en)	2019-03-12	2022-01-19	Arixa Pharmaceuticals, Inc.	Crystalline form of an avibactam derivative
US12162883B2 (en)	2019-04-26	2024-12-10	Merck Sharp & Dohme Llc	Process for the preparation of intermediates useful for making (2S,5R)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
JP7647110B2 (ja) *	2020-01-22	2025-03-18	日油株式会社	ポリエーテルエステル化合物
US20230365561A1 (en)	2020-09-01	2023-11-16	Ningxia Academy Of Agricul Ture And Forestry Sciences	Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) *	2020-09-07	2022-03-10	Ningxia Academy Of Agriculture And Forestry Sciences	Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
CN111943950B (zh) *	2020-09-10	2022-03-29	山东安信制药有限公司	一种瑞来巴坦的制备方法
WO2022233181A1 (en)	2021-05-07	2022-11-10	Ningxia Academy Of Agriculture And Forestry Sciences	Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
US11814385B2 (en) *	2021-06-25	2023-11-14	University Of South Florida	Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2023220324A1 (en) *	2022-05-11	2023-11-16	The Regents Of The University Of Colorado A Body Corporate	Antibiotic composition and methods of use thereof
CN117384169B (zh) *	2022-07-05	2025-10-17	福安药业集团重庆三禾兴医药科技有限公司	一类噻唑胺-二氮杂双环辛酮缀合衍生物及其用途
GB202306826D0 (en)	2023-05-09	2023-06-21	Adjutec Pharma As	Therapy
GB202306833D0 (en)	2023-05-09	2023-06-21	Adjutec Pharma As	Therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5071843A (en)	1978-07-24	1991-12-10	Merck & Co., Inc.	Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4880793A (en)	1978-07-24	1989-11-14	Merck & Co., Inc.	Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4616038A (en)	1978-07-24	1986-10-07	Merck & Co., Inc.	Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4539208A (en)	1980-09-17	1985-09-03	Merck & Co., Inc.	Combination of thienamycin-type antibiotics with dipeptidase inhibitors
EP0508234B1 (de)	1991-04-11	1996-07-24	F. Hoffmann-La Roche Ag	Beta-Lactame
ATE177099T1 (de)	1993-12-29	1999-03-15	Pfizer	Diazabicyclische neurokinin antagonisten
JP3199300B2 (ja) *	1994-05-09	2001-08-13	三共株式会社	１−メチルカルバペネム誘導体
JP2965922B2 (ja) *	1995-12-21	1999-10-18	三共株式会社	１−メチルカルバペネム誘導体
PT882728E (pt)	1995-12-21	2002-11-29	Sankyo Co	Derivados de 1-metilcarbapenem
JP2955276B2 (ja) *	1997-06-19	1999-10-04	三共株式会社	１−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja) *	1998-03-19	2010-06-30	富山化学工業株式会社	５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
ES2250150T3 (es)	1999-07-06	2006-04-16	Methylgene, Inc.	Inhibidores de sulfonamidometilfosfonato de la beta-lactamasa.
CN1217932C (zh) *	1999-08-10	2005-09-07	英国生物技术药物有限公司	抗菌剂
FR2812635B1 (fr)	2000-08-01	2002-10-11	Aventis Pharma Sa	Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
JP2002212182A (ja) *	2000-11-16	2002-07-31	Sankyo Co Ltd	１−メチルカルバペネム誘導体
BR0115454A (pt)	2000-11-16	2003-09-23	Sankyo Co	Composto de 1-metilcarbapenem ou um sal ou derivado de éster deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal ou derivado de éster deste farmaceuticamente aceitável
FR2825705B1 (fr)	2001-06-08	2005-05-20	Aventis Pharma Sa	Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) *	2002-01-28	2006-10-20	Aventis Pharma Sa	Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja) *	2002-05-15	2004-02-12	Sankyo Co Ltd	１−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) *	2002-12-06	2008-10-21	Novexel	Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
EP2295404A3 (en)	2003-07-09	2011-05-11	Paratek Pharmaceuticals, Inc.	Substituted tetracycline compounds
US6984652B2 (en)	2003-09-05	2006-01-10	Warner-Lambert Company Llc	Gyrase inhibitors
WO2005033129A1 (de)	2003-10-01	2005-04-14	Bayer Healthcare Ag	Antibakterielle amid-makrozyklen
WO2005082050A2 (en)	2004-02-24	2005-09-09	Ssci, Inc.	Analysis and screening of solid forms using the atomic pair distribution function
DK2484680T3 (da) *	2005-12-07	2013-09-08	Basilea Pharmaceutica Ag	Nyttige kombinationer af monolactam-antibiotika med beta-lactamase-inhibitorer
EP2069347A2 (en)	2006-09-27	2009-06-17	Merck & Co., Inc.	Novel inhibitors of beta-lactamase
WO2009091856A2 (en) *	2008-01-18	2009-07-23	Merck & Co., Inc.	Beta-lactamase inhibitors

2009
- 2009-01-15 WO PCT/US2009/031047 patent/WO2009091856A2/en not_active Ceased
- 2009-01-15 PL PL13180969T patent/PL2666774T3/pl unknown
- 2009-01-15 MX MX2010007823A patent/MX2010007823A/es active IP Right Grant
- 2009-01-15 DK DK13180969.1T patent/DK2666774T3/en active
- 2009-01-15 MY MYPI2010003255A patent/MY162532A/en unknown
- 2009-01-15 UA UAA201010164A patent/UA101966C2/ru unknown
- 2009-01-15 CN CN201210277503.4A patent/CN102827067B/zh active Active
- 2009-01-15 SI SI200931147T patent/SI2666774T1/sl unknown
- 2009-01-15 RS RS20130511A patent/RS53052B/sr unknown
- 2009-01-15 SI SI200930777T patent/SI2231667T1/sl unknown
- 2009-01-15 CA CA2712783A patent/CA2712783C/en active Active
- 2009-01-15 PT PT97014872T patent/PT2231667E/pt unknown
- 2009-01-15 CN CN200980102425.0A patent/CN101918407B/zh active Active
- 2009-01-15 JP JP2010543219A patent/JP5038509B2/ja active Active
- 2009-01-15 RU RU2010134425/04A patent/RU2445314C9/ru active
- 2009-01-15 EP EP09701487.2A patent/EP2231667B1/en active Active
- 2009-01-15 HR HRP20131123AT patent/HRP20131123T1/hr unknown
- 2009-01-15 US US12/812,763 patent/US8487093B2/en active Active
- 2009-01-15 RS RS20150154A patent/RS53862B1/sr unknown
- 2009-01-15 ES ES09701487T patent/ES2433744T3/es active Active
- 2009-01-15 DK DK09701487.2T patent/DK2231667T3/da active
- 2009-01-15 PT PT131809691T patent/PT2666774E/pt unknown
- 2009-01-15 PL PL09701487T patent/PL2231667T3/pl unknown
- 2009-01-15 ME MEP-2013-511A patent/ME02089B/me unknown
- 2009-01-15 EP EP13180969.1A patent/EP2666774B1/en active Active
- 2009-01-15 AU AU2009206119A patent/AU2009206119C1/en active Active
- 2009-01-15 NZ NZ586861A patent/NZ586861A/en unknown
- 2009-01-15 KR KR1020107015963A patent/KR101648728B1/ko active Active
- 2009-01-15 KR KR1020167021668A patent/KR101800610B1/ko active Active
- 2009-01-15 ES ES13180969.1T patent/ES2533826T3/es active Active
- 2009-01-15 BR BRPI0906871-6A patent/BRPI0906871B1/pt active IP Right Grant
2010
- 2010-06-15 IL IL206395A patent/IL206395A/en active IP Right Grant
- 2010-06-30 NI NI201000115A patent/NI201000115A/es unknown
- 2010-07-12 HN HN2010001395A patent/HN2010001395A/es unknown
- 2010-07-15 EC EC2010010345A patent/ECSP10010345A/es unknown
- 2010-07-16 DO DO2010000218A patent/DOP2010000218A/es unknown
- 2010-07-16 MA MA33026A patent/MA32025B1/fr unknown
- 2010-07-21 CO CO10088709A patent/CO6331438A2/es active IP Right Grant
- 2010-07-27 ZA ZA2010/05333A patent/ZA201005333B/en unknown
- 2010-08-10 CR CR11626A patent/CR11626A/es unknown
- 2010-10-26 EC EC2010010568A patent/ECSP10010568A/es unknown
2011
- 2011-05-26 JP JP2011118249A patent/JP5597164B2/ja active Active
2012
- 2012-05-22 JP JP2012116243A patent/JP5422020B2/ja active Active
2013
- 2013-06-06 US US13/911,549 patent/US20130274475A1/en not_active Abandoned
- 2013-12-03 CY CY20131101079T patent/CY1114900T1/el unknown
2015
- 2015-03-10 HR HRP20150269TT patent/HRP20150269T1/hr unknown
- 2015-03-23 CY CY20151100288T patent/CY1116243T1/el unknown
2020
- 2020-06-25 NL NL301050C patent/NL301050I2/nl unknown
- 2020-06-25 NL NL301051C patent/NL301051I2/nl unknown
- 2020-06-30 LU LU00165C patent/LUC00165I2/fr unknown
- 2020-07-03 LT LTPA2020517C patent/LTPA2020517I1/lt unknown
- 2020-07-03 LT LTPA2020516C patent/LTC2231667I2/lt unknown
- 2020-07-03 LT LTPA2020518C patent/LTC2666774I2/lt unknown
- 2020-07-09 HU HUS2000023C patent/HUS2000023I1/hu unknown
- 2020-07-09 HU HUS2000024C patent/HUS2000024I1/hu unknown
- 2020-07-10 FR FR20C1031C patent/FR20C1031I2/fr active Active
- 2020-07-10 FR FR20C1030C patent/FR20C1030I2/fr active Active
- 2020-07-10 FR FR20C1032C patent/FR20C1032I2/fr active Active
- 2020-07-15 CY CY2020024C patent/CY2020024I1/el unknown
- 2020-07-15 CY CY2020025C patent/CY2020025I2/el unknown
- 2020-07-15 CY CY2020023C patent/CY2020023I1/el unknown
- 2020-08-10 NO NO2020024C patent/NO2020024I1/no unknown
- 2020-08-10 NO NO2020022C patent/NO2020022I1/no unknown
- 2020-08-10 NO NO2020023C patent/NO2020023I1/no unknown

Also Published As

Publication number	Publication date
CY2020025I1 (el)	2020-11-25
ES2533826T3 (es)	2015-04-15
AU2009206119C1 (en)	2016-05-26
HUS000504I2 (hu)	2021-03-29
EP2231667B1 (en)	2013-09-04
SI2231667T1 (sl)	2013-12-31
FR20C1032I1 (nl)	2020-02-10
EP2231667A2 (en)	2010-09-29
HK1186180A1 (en)	2014-03-07
ES2433744T3 (es)	2013-12-12
CA2712783A1 (en)	2009-07-23
FR20C1030I2 (fr)	2021-08-27
JP2012214475A (ja)	2012-11-08
CN101918407B (zh)	2014-02-26
CY2020023I2 (el)	2020-11-25
LTC2666774I2 (lt)	2022-01-25
UA101966C2 (en)	2013-05-27
NL301051I2 (nl)	2020-09-03
PL2231667T3 (pl)	2014-01-31
FR20C1031I1 (nl)	2020-02-10
FR20C1032I2 (fr)	2022-07-29
CY1114900T1 (el)	2016-12-14
MX2010007823A (es)	2010-08-10
DK2231667T3 (da)	2013-12-16
BRPI0906871A2 (pt)	2020-07-28
ECSP10010345A (es)	2010-08-31
JP5597164B2 (ja)	2014-10-01
DK2666774T3 (en)	2015-03-23
EP2666774B1 (en)	2015-01-07
MA32025B1 (fr)	2011-01-03
HUS2000024I1 (hu)	2021-03-29
JP5038509B2 (ja)	2012-10-03
CN101918407A (zh)	2010-12-15
CY2020025I2 (el)	2020-11-25
BRPI0906871B1 (pt)	2021-09-28
AU2009206119B2 (en)	2012-06-07
CN102827067A (zh)	2012-12-19
WO2009091856A3 (en)	2009-12-03
KR101648728B1 (ko)	2016-08-17
NO2020023I1 (no)	2020-08-10
CY2020024I2 (el)	2020-11-25
WO2009091856A2 (en)	2009-07-23
ME02089B (me)	2014-04-30
NZ586861A (en)	2011-12-22
RU2445314C9 (ru)	2013-04-10
PL2666774T3 (pl)	2015-06-30
HRP20131123T1 (hr)	2013-12-20
KR20160099117A (ko)	2016-08-19
US8487093B2 (en)	2013-07-16
ECSP10010568A (es)	2010-11-30
IL206395A (en)	2015-04-30
MY162532A (en)	2017-06-15
IL206395A0 (en)	2010-12-30
CR11626A (es)	2010-09-13
DOP2010000218A (es)	2010-08-31
RU2445314C1 (ru)	2012-03-20
SI2666774T1 (sl)	2015-04-30
AU2009206119A1 (en)	2009-07-23
KR101800610B1 (ko)	2017-11-23
CY2020024I1 (el)	2020-11-25
HRP20150269T1 (hr)	2015-04-24
LTPA2020518I1 (lt)	2020-07-27
RS53862B1 (sr)	2015-08-31
NI201000115A (es)	2011-07-08
NO2020022I1 (no)	2020-08-10
HUS000513I2 (hu)	2021-03-29
LUC00165I2 (nl)	2021-08-16
LTPA2020516I1 (lt)	2020-07-27
EP2666774A1 (en)	2013-11-27
LTC2231667I2 (lt)	2021-07-26
US20130274475A1 (en)	2013-10-17
CA2712783C (en)	2013-03-19
JP5422020B2 (ja)	2014-02-19
HN2010001395A (es)	2012-11-12
CY1116243T1 (el)	2017-03-15
PT2666774E (pt)	2015-04-13
KR20100130176A (ko)	2010-12-10
JP2011207900A (ja)	2011-10-20
US20110294777A1 (en)	2011-12-01
HK1143809A1 (en)	2011-01-14
PT2231667E (pt)	2013-12-13
CN102827067B (zh)	2015-09-23
LTPA2020517I1 (lt)	2020-07-27
CY2020023I1 (el)	2020-11-25
HUS2000023I1 (hu)	2021-03-29
CO6331438A2 (es)	2011-10-20
FR20C1031I2 (fr)	2022-07-29
JP2011510012A (ja)	2011-03-31
FR20C1030I1 (fr)	2020-02-10
NO2020024I1 (no)	2020-08-10
RS53052B (sr)	2014-04-30
ZA201005333B (en)	2011-04-28

Publication	Publication Date	Title
NL301050I2 (nl)	2020-09-03	Relebactam of het monohydraat ervan
NL300938I2 (nl)	2019-01-08	Niraparib tosylaat of niraparib tosylaat monohydraat
SMT201600267B (it)	2016-08-31	Inibitori di syk imidazopirazinici
SMT201600075B (it)	2016-04-29	Composto di diamminocarbossammide eterociclica
EP2346508A4 (en)	2012-04-18	HETEROCYCLIC KINASE HEMMER
EP2347199A4 (en)	2015-10-14	Refrigerator
EP2192838A4 (en)	2011-07-27	HETEROCYCLIC NEKROPTOSIS HEMMER
HRP20190016T1 (hr)	2019-03-08	Heterociklički spojevi i njihova upotreba
BRPI0922937A2 (pt)	2019-09-24	inibidores de pirrolopirazinil uréia quinase
DOP2012000114A (es)	2012-08-15	Inhibidor bromodominio de benzodiazepina
EP2124523A4 (en)	2010-08-04	BREEDING LINE P2428-5006090
EP2272817A4 (en)	2011-12-14	PAI-1 INHIBITORS
DOP2007000084A (es)	2007-12-31	Derivados de dihidropirazolopirimidinona
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
EP2317257A4 (en)	2015-01-21	FRIDGE
EP2267388A4 (en)	2012-05-23	FRIDGE
BRPI0906705A2 (pt)	2015-06-30	Composto heterocíclicos
LT2313364T (lt)	2021-01-25	Simetrinio dimetilarginino nustatymo būdai
BRPI0918564A2 (pt)	2015-12-01	inibidores
EP2349335A4 (en)	2012-02-08	LEVETIRACETAM IMMUNOASSAYS
EP2245393A4 (en)	2015-08-05	COOLER
CR10809A (es)	2009-06-25	Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
EP2299220A4 (en)	2012-09-19	FRIDGE
EP2320180A4 (en)	2014-05-14	FRIDGE
SMT201600031B (it)	2016-02-25	Composti eterociclici di fenossimetile